Translate AMICOR contents if you like

Showing posts with label DCV. Show all posts
Showing posts with label DCV. Show all posts

Monday, December 30, 2019

Jeremiah Stamler

Jerry Stamler

At age 100, the father of preventive medicine is still going strong — as living proof that he was right all along

By CINDY DAMPIER
CHICAGO TRIBUNE |
DEC 26, 2019 | 5:00 AM
Recomendado por AMICOR Flávio Kanter, através de seu irmão Nelson Kanter que atualmente vive nos EEUU.
Dr. Jeremiah Stamler at Northwestern University Feinberg Medical School at a celebration for his 100th birthday in the fall.
Dr. Jeremiah Stamler at Northwestern University Feinberg Medical School at a celebration for his 100th birthday in the fall. (Teresa Crawford/Northwestern University)/.../

O Jerry foi muito importante para mim, desde sua participação na  2nd. National Conference on Cardiovascular Diseases, na área de Community Services & Education que usei como informação epidemiológica pela inexistência de informações nossas, para a Análise Institucional da SS da qual participei em 1971-72. Vim a conhecer pessoalmente o Professor Stamler posteriormente, mas suas informações relacionadas com os EEUU deram-me respaldo para dizer ao recém empossado Secretário da Saúde - dr Jair Soares, que eu queria licença para deixar meu posto, e assumir a disciplina de Cardiologia na PUCRS, porque onde eu estava não havia programa preventivo e de saúde pública na  área Cardiovascular - somente fazíamos assistência, o que eu poderia continuar fazendo na nova instituição. Foi quando ele me surpreendeu com a pergunta desafiadora: "porque não fazes uma proposta?"
Assim começou a abordagem preventiva de doenças cardiovasculares e outras doenças crônicas no Rio Grande do Sul, depois no Brasil e em muitos países pelo mundo afora com o apoio da Organização Panamericana da Saúde/Organização Mundial da Saúde, abordando Fatores de Risco, chegando à Promoção da Saúde.

Do The Lancet OBITUARY| VOLUME 399, ISSUE 10329P1044, MARCH 12, 2022

Jeremiah Stamler

Published:March 12, 2022DOI:https://doi.org/10.1016/S0140-6736(22)00421-4Figure thumbnail fx1
Pioneer in cardiovascular disease prevention. He was born in Brooklyn, NY, USA, on Oct 27, 1919 and died in Sag Harbor, NY, USA, on Jan 26, 2022 aged 102 years.
Seldom has a person's life offered more compelling support to the value of his own convictions than that of Jeremiah Stamler, founding chair and Professor Emeritus of Preventive Medicine at Northwestern University's Feinberg School of Medicine in Chicago, IL, USA. He spent his career helping to identify risk factors for cardiovascular disease and campaigning to have them recognised—he also enjoyed the Mediterranean diet he advocated and lived to become a centenarian. “He was one of a small group of people who really founded the discipline of cardiovascular epidemiology”, says Donald Lloyd-Jones, Chair of Feinberg's Department of Preventive Medicine and Eileen M Foell Professor of Heart Research. Paul Elliott, Professor of Epidemiology and Public Health Medicine at Imperial College London, UK, agrees: “Jerry was a colossus in cardiovascular epidemiology and prevention.”
The circulatory system dominated Stamler's research from the outset. After a bachelor's degree at New York's Columbia University he went on to study medicine at what is now SUNY Downstate Health Sciences University in Brooklyn. He graduated in 1943 and served as an army radiologist before taking a job at the Michael Reese Hospital in Chicago. “He started in the late 1940s in the laboratory of [cardiologist] Louis Katz, whose research included feeding cholesterol-rich chow to chickens,” says Lloyd-Jones, who is also President of the American Heart Association. The birds developed a build-up of atherosclerotic plaque. Stamler himself studied the effects on the cardiovascular system not only of lipids, but of hormones, blood pressure, and diet more generally. In 1958 he moved to Chicago, where he joined the Board of Health and organised its first heart disease control programme, as well as Northwestern's Department of Medicine.
Before the 1960s and 1970s, heart disease was still not much related to risk factors and behaviour. Stamler set out to challenge that view. In 1972 he was appointed chair of Feinberg's newly created Department of Community Health and Preventive Medicine and began organising or taking part in national and later international trials that identified the risk factors for heart disease. “He and others demonstrated through animal studies and in human population studies that these risk factors were likely causing atherosclerosis and heart attacks”, says Philip Greenland, Harry W Dingman Professor of Cardiology and of Preventive Medicine at Northwestern. But the possibility of intervening to prevent heart attacks was still considered radical. “Stamler was a pioneer of optimal assessment techniques in diet”, says Lloyd-Jones. “He did some of the best studies ever.” One such was Intersalt, a 1988 study of more than 10 000 people aged 20–59 years from 32 countries that showed a clear link between salt intake and blood pressure. Paul Elliott, a junior research fellow at the time of the study, helped in its design. The US salt industry's trade body, the now defunct Salt Institute, was unhappy with its findings. “The Salt Institute demanded a reanalysis of data to their specification, which the investigators willingly carried out”, Elliott recalls. “The publication of the reanalysis in 1996 showed, if anything, stronger findings on salt and rise in blood pressure with age than the original analysis.”
Some of Stamler's fellow doctors had joined the chorus of dissent. As Greenland recalls: “There were editorials by prominent cardiologists…saying…it's time to give up on this crazy idea that heart disease can be prevented”. But Stamler was undeterred. “One of the things that characterised him was his sense of what is right and what is true, and if you believe something is right and true you fight for it,” says Greenland. This outlook extended beyond matters of health. In 1965, Stamler was summoned to appear before the US Government House Un-American Activities Committee (HUAC), accused of having been a member of the Communist Party. The accusation was false, but Stamler refused to testify, argued that the HUAC was unconstitutional, was charged with contempt of Congress, and filed a lawsuit against the HUAC. The contempt charge was dropped, but not until 1973.
Stamler “was rigorous and intensive in his work, and persistent”, says Greenland. “You never doubted he was a towering intellect when you were in his presence”, says Lloyd-Jones. “But he was gentle and good at listening…He really valued the people he worked with. He was intensively collaborative, and he understood that everybody on the team had something to offer.” Stamler is survived by his son, Paul, and stepsons, Jonathan and Michael.

Tuesday, June 04, 2019

Inibidores da Aromatase

Existe Alguma Preocupação Cardiovascular em Relação ao Uso deInibidores da Aromatase no Câncer de Mama?Is There Any Cardiovascular Concern Regarding the Use of Aromatase Inhibitors in Breast Cancer?
 Tatiana F. G. Galvão Hospital Israelita Albert Einstein, São Paulo, SP – Brasil Correspondência: Tatiana F. G. Galvão • Av. Albert Einstein, 627- Sala 419-Bloco A1 E-mail: tatiana.galvao@einstein.br
Palavras-chave Inibidores de Aromatase; Neoplasias de Mama; Colesterol; Glicemia; Terapia de Reposição de Estrogênio; Doenças Cardiovasculares/prevenção e controle. DOI: 10.5935/abc.20190092
O câncer de mama é a neoplasia maligna mais frequente em mulheres no mundo todo e a segunda maior causa de mortalidade por câncer.1 Devido aos avanços na prevenção, detecção precoce e tratamento, a mortalidade por câncer de mama diminuiu em quase 40% nas últimas quatro décadas.1 No entanto, este cenário otimista foi contrabalançado por um risco crescente de doença cardiovascular (DCV) em sobreviventes de câncer de mama. De fato, a DCV é uma das principais causas de mortalidade em sobreviventes de câncer de mama.2-5 Os mecanismos pelos quais esses pacientes apresentam risco cardiovascular aumentado são múltiplos, incluindo os efeitos do próprio câncer (inflamação, estresse oxidativo, estado pró-trombótico, disfunção autonômica, etc.) ou devido aos efeitos colaterais relacionados à quimioterapia e radioterapia (disfunção metabólica, cardiotoxicidade).6 Algumas dessas vias podem ter significância prognóstica: uma investigação anterior mostrou que a modulação autonômica em pacientes com câncer de mama é um preditor independente de risco cardiovascular.

Tuesday, February 06, 2018

Influenza e Doença Coronária

A AMICOR Maria Inês Reinert Azambuja está apresentando em Taos, New Mexico, apresentando minha hipótese sobre Influenza e variações na ocorrência de Doença Isquemica do Coração num Keystone Simposia sobre Aterosclerose chamado Lessons Learned and Concepts Challenged..
Quinta vou fazer uma apresentação oral.
A receptividade está sendo legal, especialmente de mais jovens... Ficam surpresos... nunca ouviram nada assim... 


Saturday, December 07, 2013

retrograde gene therapy

First use of retrograde gene therapy on a human heart

Procedure delivers stem cells to the heart to repair damaged muscle and arteries
December 2, 2013
JuventasRetrograde_11-04-13a
Dr. Patel performing the operation on patient Ernie Lively on Nov. 7 (credit: University of Utah)
A new procedure designed to deliver stem cells to the heart to repair damaged muscle and arteries in the most minimally invasive way possible has been performed for the first time by Amit Patel, M.D., director of Clinical Regenerative Medicine and Tissue Engineering and an associate professor in the Division of Cardiothoracic Surgery at the University of Utah School of Medicine.
Patel started investigating cell and gene-based therapies for the treatment of heart disease 12 years ago, but only recently received FDA approval to try the therapy on Lively, who was the first of several patients anxious to receive the treatment.
More than 6 million people are currently living with heart failure. As the condition progresses, patients’ options are usually limited to a heart transplant or assist devices, such as an artificial heart. Patel wanted to find a way to intervene in the progression of heart failure before a patient advanced to the point of needing a heart transplant or device./.../

Sunday, April 15, 2012

Prevenção de DCV e Promoção da Saúde


Ciência & Saúde Coletiva Problemas de Saúde, Segundo Ciclos de Vida e GêneroSumárioCiênc. saúde coletiva vol.17 no.1 Rio de Janeiro jan. 2012 
Debate
·  A promoção da saúde e a prevenção integrada dos fatores de risco para doenças cardiovasculares
Ribeiro, Amanda GomesCotta, Rosângela Minardi MitreRibeiro, Sônia Machado Rocha

        · resumo em Português | Inglês     · texto em Português     · pdf em Português     · press release em Português
 Debatedores
·  Prevenção de doenças cardiovasculares e promoção da saúde
Achutti, Aloyzio

        · texto em Português     · pdf em Português


 Editorial
·  Divulgação científica: a última e imprescindível etapa do processo científico


        · texto em Português | Inglês     · pdf em Português | Inglês

Thursday, March 31, 2011

Interessa saber e discutir sobre as causas das DCV?

pOR: Aloyzio Achutti e Maria Inês Reinert Azambuja
INTRODUÇÃO 
Interessa para tentar controlá-las.
Mas como?
Teoricamente o conhecimento da patogenia e da epidemiologia das doenças deve ajudar a prevenir o  Surgimento (incidência), deter ou retardar sua evolução, precisar o diagnóstico (de cada caso e da população) e adequar intervenções (não apenas o tratamento individual com medicamentos e técnicas cirúrgicas, mas também utilizando recursos de alcance populacional, como políticas e mídia).
No mundo todo, longitudinalmente, ao longo do tempo, tem se observado mudanças no perfil das doenças, e também das cardiovasculares. Muita controvérsia existe ainda na tentativa de explicar as modificações ocorridas. Quanto pode ser atribuído às intervenções estritamente médicas (melhor diagnóstico, tratamento, (prevenção e reabilitação) e às mudanças concomitantes no perfil de outras doenças, na longevidade e em outros fatores desconhecidos?
A identificação dos fatores de risco clássicos e a busca de novos fatores candidatos têm orientado o estadiamento individual dos pacientes e a conduta na prescrição de medidas de prevenção secundária (quando já existe a doença) ou de prevenção primária (enquanto a doença ainda não se manifesta)/.../